Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
作者： M. Hänel , K. Friedrichsen , A. Hänel , R. Herbst , A. Morgner
DOI: 10.1159/000055107
关键词:
摘要: Background: This study was performed to examine the feasibility and toxicity of combination mitoxantrone, fludarabine, cytarabine as bolus (B) or continuous infusion (CI) an
karger.com
sci-hub.se 参考文章(20)
N.C. Gorin, Autologous stem cell transplantation in acute myelocytic leukemia. Blood. ,vol. 92, pp. 1073- 1090 ,(1998) , 10.1182/BLOOD.V92.4.1073.416K35_1073_1090
SH Kaufmann, JE Karp, RJ Jones, CB Miller, E Schneider, LA Zwelling, K Cowan, K Wendel, PJ Burke, Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia Blood. ,vol. 83, pp. 517- 530 ,(1994) , 10.1182/BLOOD.V83.2.517.517
V Gandhi, E Estey, M J Keating, W Plunkett, Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology. ,vol. 11, pp. 116- 124 ,(1993) , 10.1200/JCO.1993.11.1.116
Javier De La Sernas, Jose Francisco Tomás, Carlos Solano, Maria Luisa García De Paredes, Joaquín Campbell, Carlos Grande, Joaquín Diaz-Mediavilla, Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. ,vol. 25, pp. 365- 372 ,(1997) , 10.3109/10428199709114175
Elihu Estey, William Plunkett, Varsha Gandhi, Mary Beth Rios, Hagop Kantarjian, Michael J. Keating, Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia & Lymphoma. ,vol. 9, pp. 343- 350 ,(1993) , 10.3109/10428199309148532
X. Thomas, E. Archimbaud, Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematology and Cell Therapy. ,vol. 39, pp. 163- 174 ,(1997) , 10.1007/S00282-997-0163-8
Volker Heinemann, David Murray, Ronald Walters, Raymond E. Meyn, William Plunkett, Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemotherapy and Pharmacology. ,vol. 22, pp. 205- 210 ,(1988) , 10.1007/BF00273412
W Kern, , C Aul, G Maschmeyer, R Schönrock-Nabulsi, WD Ludwig, A Bartholomäus, P Bettelheim, B Wörmann, T Büchner, W Hiddemann, Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison Leukemia. ,vol. 12, pp. 1049- 1055 ,(1998) , 10.1038/SJ.LEU.2401066
Susan Loughlin, Varsha Gandhi, William Plunkett, L. A. Zwelling, The effect of 9-β-D-arabinofuranosyl-2-fluoroadenine and 1-β-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells Cancer Chemotherapy and Pharmacology. ,vol. 38, pp. 261- 268 ,(1996) , 10.1007/S002800050480
Marco Montillo, Salvatore Mirto, Maria Concetta Petti, Roberto Latagliata, Silvana Magrin, Antonio Pinto, Vittorina Zagonel, Giuseppina Mele, Alessandra Tedeschi, Felicetto Ferrara, Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia American Journal of Hematology. ,vol. 58, pp. 105- 109 ,(1998) , 10.1002/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W